Kestra Advisory Services LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 25.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,625 shares of the company’s stock after selling 1,269 shares during the quarter. Kestra Advisory Services LLC’s holdings in IDEXX Laboratories were worth $1,181,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Van ECK Associates Corp increased its holdings in IDEXX Laboratories by 6.1% in the third quarter. Van ECK Associates Corp now owns 12,723 shares of the company’s stock valued at $4,145,000 after buying an additional 737 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in IDEXX Laboratories by 3.2% during the second quarter. Illinois Municipal Retirement Fund now owns 11,388 shares of the company’s stock worth $3,994,000 after purchasing an additional 353 shares in the last quarter. Wealthspire Advisors LLC grew its holdings in IDEXX Laboratories by 9.1% in the second quarter. Wealthspire Advisors LLC now owns 1,862 shares of the company’s stock valued at $653,000 after purchasing an additional 155 shares during the period. Mutual of America Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.2% in the second quarter. Mutual of America Capital Management LLC now owns 12,306 shares of the company’s stock valued at $4,316,000 after buying an additional 144 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its stake in shares of IDEXX Laboratories by 2.7% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 164,262 shares of the company’s stock worth $57,612,000 after buying an additional 4,242 shares during the period. 87.90% of the stock is currently owned by institutional investors and hedge funds.
IDEXX Laboratories Trading Down 1.9 %
Shares of IDXX opened at $486.70 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $317.06 and a 12-month high of $574.33. The firm has a market capitalization of $40.31 billion, a P/E ratio of 61.84, a P/E/G ratio of 3.00 and a beta of 1.18. The firm has a 50-day moving average price of $431.01 and a 200 day moving average price of $387.98. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 1.60.
Insiders Place Their Bets
In other news, Director Daniel M. Junius sold 3,046 shares of the company’s stock in a transaction on Monday, December 5th. The stock was sold at an average price of $424.91, for a total value of $1,294,275.86. Following the transaction, the director now owns 2,968 shares of the company’s stock, valued at approximately $1,261,132.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Daniel M. Junius sold 3,046 shares of the business’s stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $424.91, for a total value of $1,294,275.86. Following the sale, the director now directly owns 2,968 shares in the company, valued at approximately $1,261,132.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 13,230 shares of the stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $382.49, for a total transaction of $5,060,342.70. Following the transaction, the chief executive officer now directly owns 62,307 shares of the company’s stock, valued at approximately $23,831,804.43. The disclosure for this sale can be found here. Insiders sold a total of 30,516 shares of company stock valued at $12,541,681 over the last quarter. 2.06% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on IDXX shares. JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $525.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, October 17th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 3rd. TheStreet raised IDEXX Laboratories from a “c+” rating to a “b-” rating in a report on Friday, November 25th. Atlantic Securities lowered their price target on IDEXX Laboratories from $490.00 to $470.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 2nd. Finally, Morgan Stanley reduced their price objective on IDEXX Laboratories from $573.00 to $543.00 and set an “overweight” rating for the company in a research note on Tuesday, November 15th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $473.13.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.